Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
65.00    -0.40 (-0.61%)
Bid:
64.80
Ask:
65.00
Spread: 0.20 (0.309%)
Market Cap: £574.23m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Form 8.3 - IP Group Plc

Today 14:12

Form 8.3 - IP Group Plc

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Rathbones Group Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeIP Group Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure23/06/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:2p Ordinary Shares
 InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:9,598,1651.08%  
(2) Cash-settled derivatives:    
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:9,598,1651.08%  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
2p Ordinary SharesSale7,10065.5002p

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
     

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
2p Ordinary Shares   

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?No

Date of disclosure:24/06/2026
Contact name:Hannah Collins – Compliance Department
Telephone number:0151 243 7103

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Date   Source Headline
11th Jan 20237:00 amRNSPortfolio company Oxbotica raises $140m Series C
3rd Jan 202311:48 amRNSTotal Voting Rights
12th Dec 20224:58 pmRNSAGM post-meeting shareholder engagement update
7th Dec 20224:39 pmRNSHolding(s) in Company
5th Dec 20227:00 amRNSIstesso announces FDA Fast Track for MBS2320
2nd Dec 202211:38 amRNSPortfolio company funding leads to £36m gain
30th Nov 202210:41 amRNSTotal Voting Rights
21st Nov 20222:13 pmRNSLife sciences presentation postponed
2nd Nov 20223:51 pmRNSInvestor presentation on life sciences
1st Nov 20228:59 amRNSNotification of major holdings
31st Oct 20224:35 pmRNSDirector/PDMR Shareholding
27th Oct 20224:55 pmRNSPDMR Dealing – SAYE Exercise
24th Oct 20226:02 pmRNSHolding(s) in Company
14th Oct 20229:42 amRNSHolding(s) in Company
30th Sep 202210:39 amRNSTotal Voting Rights
21st Sep 20225:29 pmRNSHolding(s) in Company
20th Sep 20226:10 pmRNSDirector/PDMR Shareholding
15th Sep 20224:41 pmRNSInvestor presentation
14th Sep 20224:33 pmRNSFurther re Scrip Dividend
13th Sep 20226:00 pmRNSFurther re Interim Scrip Dividend
13th Sep 20227:01 amEQSIP Group Trust (IPO): Initiation — International investor in impactful innovation
7th Sep 20224:33 pmRNSDirector/PDMR Shareholding, SAYE scheme
31st Aug 20228:51 amRNSIstesso starts Phase 2b trial of MBS2320
30th Aug 202212:59 pmRNSCash acquisition of portfolio company Diurnal
18th Aug 20229:25 amRNSScrip Dividend Reference Price
11th Aug 202210:50 amRNSHolding(s) in Company
3rd Aug 20227:00 amRNSHalf-yearly results
2nd Aug 20227:00 amRNSPortfolio company Hysata completes funding round
13th Jul 20229:30 amRNSNotice of Results
30th Jun 20225:46 pmRNSRSP awards and Scrip Elections
29th Jun 20229:16 amRNSFurther re Scrip Dividend
22nd Jun 20227:00 amRNSLaunches ‘Kiko Ventures’ cleantech platform
16th Jun 202211:27 amRNSDirector/PDMR Shareholding
14th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:30 amRNSTR-1
6th Jun 20228:14 amRNSScrip Dividend Reference Price
1st Jun 20223:23 pmRNSInvestor presentation; AGM arrangements
13th May 202212:43 pmRNSDirector Declaration
9th May 20225:21 pmRNSNotice of AGM, Annual Report
29th Apr 20223:46 pmRNSTotal Voting Rights
27th Apr 20226:16 pmRNSDirector/PDMR Shareholding
25th Apr 20226:09 pmRNSDBSP awards; Director/PDMR shareholding
5th Apr 20227:00 amRNSPortfolio company First Light achieves fusion
16th Mar 20227:00 amRNSAnnual Results
7th Mar 20228:00 amRNSPortfolio co Microbiotica completes £50m raise
2nd Mar 20229:19 amRNSNotice of Results
14th Feb 20227:00 amRNSPortfolio company Bramble raises £35m
14th Feb 20227:00 amRNSPortfolio co First Light completes $45m fund raise
28th Jan 20225:02 pmRNSTransaction in Own Shares
28th Jan 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.